Single User License
INR 170050
Site License
INR 340100
Corporate User License
INR 510150

Service Tax Additional

select a format
Price

Single User License
USD 2500
Site License
USD 5000
Corporate User License
USD 7500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Type 2 Diabetes-Pipeline Review, H1 2015

Type 2 Diabetes-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Type 2 Diabetes-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Type 2 Diabetes-Pipeline Review, H1 2015', provides an overview of the Type 2 Diabetes's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Type 2 Diabetes, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type 2 Diabetes and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Type 2 Diabetes

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Type 2 Diabetes and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Type 2 Diabetes products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Type 2 Diabetes pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Type 2 Diabetes

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Type 2 Diabetes pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

Introduction 12

Type 2 Diabetes Overview 13

Therapeutics Development 14

Type 2 Diabetes-Therapeutics under Development by Companies 16

Type 2 Diabetes-Therapeutics under Investigation by Universities/Institutes 35

Type 2 Diabetes-Pipeline Products Glance 39

Type 2 Diabetes-Products under Development by Companies 43

Type 2 Diabetes-Products under Investigation by Universities/Institutes 79

Type 2 Diabetes-Companies Involved in Therapeutics Development 82

Type 2 Diabetes-Therapeutics Assessment 292

Drug Profiles 318

Small Molecules to Inhibit CDK5 for Type 2 Diabetes-Drug Profile 907

Type 2 Diabetes-Recent Pipeline Updates 1005

Type 2 Diabetes-Dormant Projects 1117

Type 2 Diabetes-Discontinued Products 1146

Type 2 Diabetes-Product Development Milestones 1162

Appendix 1169

List of Tables

Number of Products under Development for Type 2 Diabetes, H1 2015 72

Number of Products under Development for Type 2 Diabetes-Comparative Analysis, H1 2015 73

Number of Products under Development by Companies, H1 2015 75

Number of Products under Development by Companies, H1 2015 (Contd..1) 76

Number of Products under Development by Companies, H1 2015 (Contd..2) 77

Number of Products under Development by Companies, H1 2015 (Contd..3) 78

Number of Products under Development by Companies, H1 2015 (Contd..4) 79

Number of Products under Development by Companies, H1 2015 (Contd..5) 80

Number of Products under Development by Companies, H1 2015 (Contd..6) 81

Number of Products under Development by Companies, H1 2015 (Contd..7) 82

Number of Products under Development by Companies, H1 2015 (Contd..8) 83

Number of Products under Development by Companies, H1 2015 (Contd..9) 84

Number of Products under Development by Companies, H1 2015 (Contd..10) 85

Number of Products under Development by Companies, H1 2015 (Contd..11) 86

Number of Products under Development by Companies, H1 2015 (Contd..12) 87

Number of Products under Development by Companies, H1 2015 (Contd..13) 88

Number of Products under Development by Companies, H1 2015 (Contd..14) 89

Number of Products under Development by Companies, H1 2015 (Contd..15) 90

Number of Products under Development by Companies, H1 2015 (Contd..16) 91

Number of Products under Development by Companies, H1 2015 (Contd..17) 92

Number of Products under Investigation by Universities/Institutes, H1 2015 94

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 95

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 96

Comparative Analysis by Late Stage Development, H1 2015 97

Comparative Analysis by Clinical Stage Development, H1 2015 98

Comparative Analysis by Early Stage Development, H1 2015 99

Comparative Analysis by Unknown Stage Development, H1 2015 100

Products under Development by Companies, H1 2015 101

Products under Development by Companies, H1 2015 (Contd..1) 102

Products under Development by Companies, H1 2015 (Contd..2) 103

Products under Development by Companies, H1 2015 (Contd..3) 104

Products under Development by Companies, H1 2015 (Contd..4) 105

Products under Development by Companies, H1 2015 (Contd..5) 106

Products under Development by Companies, H1 2015 (Contd..6) 107

Products under Development by Companies, H1 2015 (Contd..7) 108

Products under Development by Companies, H1 2015 (Contd..8) 109

Products under Development by Companies, H1 2015 (Contd..9) 110

Products under Development by Companies, H1 2015 (Contd..10) 111

Products under Development by Companies, H1 2015 (Contd..11) 112

Products under Development by Companies, H1 2015 (Contd..12) 113

Products under Development by Companies, H1 2015 (Contd..13) 114

Products under Development by Companies, H1 2015 (Contd..14) 115

Products under Development by Companies, H1 2015 (Contd..15) 116

Products under Development by Companies, H1 2015 (Contd..16) 117

Products under Development by Companies, H1 2015 (Contd..17) 118

Products under Development by Companies, H1 2015 (Contd..18) 119

Products under Development by Companies, H1 2015 (Contd..19) 120

Products under Development by Companies, H1 2015 (Contd..20) 121

Products under Development by Companies, H1 2015 (Contd..21) 122

Products under Development by Companies, H1 2015 (Contd..22) 123

Products under Development by Companies, H1 2015 (Contd..23) 124

Products under Development by Companies, H1 2015 (Contd..24) 125

Products under Development by Companies, H1 2015 (Contd..25) 126

Products under Development by Companies, H1 2015 (Contd..26) 127

Products under Development by Companies, H1 2015 (Contd..27) 128

Products under Development by Companies, H1 2015 (Contd..28) 129

Products under Development by Companies, H1 2015 (Contd..29) 130

Products under Development by Companies, H1 2015 (Contd..30) 131

Products under Development by Companies, H1 2015 (Contd..31) 132

Products under Development by Companies, H1 2015 (Contd..32) 133

Products under Development by Companies, H1 2015 (Contd..33) 134

Products under Development by Companies, H1 2015 (Contd..34) 135

Products under Development by Companies, H1 2015 (Contd..35) 136

Products under Investigation by Universities/Institutes, H1 2015 137

Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 138

Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 139

Type 2 Diabetes-Pipeline by ActogeniX NV, H1 2015 140

Type 2 Diabetes-Pipeline by Addex Therapeutics Ltd, H1 2015 141

Type 2 Diabetes-Pipeline by Advinus Therapeutics Ltd., H1 2015 142

Type 2 Diabetes-Pipeline by Aegis Therapeutics, LLC, H1 2015 143

Type 2 Diabetes-Pipeline by AFFiRiS AG, H1 2015 144

Type 2 Diabetes-Pipeline by AlbireoPharma, H1 2015 145

Type 2 Diabetes-Pipeline by Alchemia Limited, H1 2015 146

Type 2 Diabetes-Pipeline by Alize Pharma SAS, H1 2015 147

Type 2 Diabetes-Pipeline by Allozyne, Inc., H1 2015 148

Type 2 Diabetes-Pipeline by AlphaMab Co., Ltd, H1 2015 149

Type 2 Diabetes-Pipeline by Ambrx, Inc., H1 2015 150

Type 2 Diabetes-Pipeline by Amgen Inc., H1 2015 151

Type 2 Diabetes-Pipeline by Anchor Therapeutics, Inc., H1 2015 152

Type 2 Diabetes-Pipeline by AntriaBio, Inc., H1 2015 153

Type 2 Diabetes-Pipeline by Ardelyx, Inc., H1 2015 154

Type 2 Diabetes-Pipeline by Arena Pharmaceuticals, Inc., H1 2015 155

Type 2 Diabetes-Pipeline by Arisaph Pharmaceuticals, Inc., H1 2015 156

Type 2 Diabetes-Pipeline by Array BioPharma Inc., H1 2015 157

Type 2 Diabetes-Pipeline by Arrien Pharmaceuticals, LLC, H1 2015 158

Type 2 Diabetes-Pipeline by Artery Therapeutics, Inc., H1 2015 159

Type 2 Diabetes-Pipeline by Astellas Pharma Inc., H1 2015 160

Type 2 Diabetes-Pipeline by AstraZeneca PLC, H1 2015 161

Type 2 Diabetes-Pipeline by AUS Bio Limited, H1 2015 162

Type 2 Diabetes-Pipeline by Avaxia Biologics, Inc., H1 2015 163

Type 2 Diabetes-Pipeline by Bayer AG, H1 2015 164

Type 2 Diabetes-Pipeline by Betagenon AB, H1 2015 165

Type 2 Diabetes-Pipeline by Biocon Limited, H1 2015 166

Type 2 Diabetes-Pipeline by Biodel Inc., H1 2015 167

Type 2 Diabetes-Pipeline by Biogenomics Limited, H1 2015 168

Type 2 Diabetes-Pipeline by BioRestorative Therapies, Inc., H1 2015 169

Type 2 Diabetes-Pipeline by BioTherapeutics Inc., H1 2015 170

Type 2 Diabetes-Pipeline by Boehringer Ingelheim GmbH, H1 2015 171

Type 2 Diabetes-Pipeline by Boston Therapeutics, Inc., H1 2015 172

Type 2 Diabetes-Pipeline by Braasch Biotech LLC, H1 2015 173

Type 2 Diabetes-Pipeline by Bridge Bioresearch Plc, H1 2015 174

Type 2 Diabetes-Pipeline by Bristol-Myers Squibb Company, H1 2015 175

Type 2 Diabetes-Pipeline by C4X Discovery Ltd, H1 2015 176

Type 2 Diabetes-Pipeline by Cardax Pharmaceuticals, Inc., H1 2015 177

Type 2 Diabetes-Pipeline by Cardiolynx AG, H1 2015 178

Type 2 Diabetes-Pipeline by Carlina Technologies SAS, H1 2015 179

Type 2 Diabetes-Pipeline by Carmot Therapeutics, Inc., H1 2015 180

Type 2 Diabetes-Pipeline by Celon Pharma Sp. z o.o., H1 2015 181

Type 2 Diabetes-Pipeline by ChemoCentryx, Inc., H1 2015 182

Type 2 Diabetes-Pipeline by Chipscreen Biosciences Ltd, H1 2015 183

Type 2 Diabetes-Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2015 184

Type 2 Diabetes-Pipeline by CJ CheilJedang Corp., H1 2015 185

Type 2 Diabetes-Pipeline by Connexios Life Sciences Pvt. Ltd., H1 2015 186

Type 2 Diabetes-Pipeline by Cortendo AB, H1 2015 187

Type 2 Diabetes-Pipeline by CSL Limited, H1 2015 188

Type 2 Diabetes-Pipeline by CTI BioPharma Corp., H1 2015 189

Type 2 Diabetes-Pipeline by CureDM, Inc., H1 2015 190

Type 2 Diabetes-Pipeline by CymaBay Therapeutics, Inc., H1 2015 191

Type 2 Diabetes-Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2015 192

Type 2 Diabetes-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 193

List of Figures

Number of Products under Development for Type 2 Diabetes, H1 2015 72

Number of Products under Development for Type 2 Diabetes-Comparative Analysis, H1 2015 73

Number of Products under Development by Companies, H1 2015 74

Number of Products under Investigation by Universities/Institutes, H1 2015 93

Comparative Analysis by Late Stage Development, H1 2015 97

Comparative Analysis by Clinical Stage Development, H1 2015 98

Comparative Analysis by Early Stage Products, H1 2015 99

Assessment by Monotherapy Products, H1 2015 350

Assessment by Combination Products, H1 2015 351

Number of Products by Top 10 Targets, H1 2015 352

Number of Products by Stage and Top 10 Targets, H1 2015 352

Number of Products by Top 10 Mechanism of Actions, H1 2015 362

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 362

Number of Products by Top 10 Routes of Administration, H1 2015 372

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 373

Number of Products by Top 10 Molecule Types, H1 2015 374

Number of Products by Stage and Top 10 Molecule Types, H1 2015 374

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

ActogeniX NV

Addex Therapeutics Ltd

Advinus Therapeutics Ltd.

Aegis Therapeutics, LLC

AFFiRiS AG

AlbireoPharma

Alchemia Limited

Alize Pharma SAS

Allozyne, Inc.

AlphaMab Co., Ltd

Ambrx, Inc.

Amgen Inc.

Anchor Therapeutics, Inc.

AntriaBio, Inc.

Ardelyx, Inc.

Arena Pharmaceuticals, Inc.

Arisaph Pharmaceuticals, Inc.

Array BioPharma Inc.

Arrien Pharmaceuticals, LLC

Artery Therapeutics, Inc.

Astellas Pharma Inc.

AstraZeneca PLC

AUS Bio Limited

Avaxia Biologics, Inc.

Bayer AG

Betagenon AB

Biocon Limited

Biodel Inc.

Biogenomics Limited

BioRestorative Therapies, Inc.

BioTherapeutics Inc.

Boehringer Ingelheim GmbH

Boston Therapeutics, Inc.

Braasch Biotech LLC

Bridge Bioresearch Plc

Bristol-Myers Squibb Company

C4X Discovery Ltd

Cardax Pharmaceuticals, Inc.

Cardiolynx AG

Carlina Technologies SAS

Carmot Therapeutics, Inc.

Celon Pharma Sp. z o.o.

ChemoCentryx, Inc.

Chipscreen Biosciences Ltd

Chong Kun Dang Pharmaceutical Corp.

CJ CheilJedang Corp.

Connexios Life Sciences Pvt. Ltd.

Cortendo AB

CSL Limited

CTI BioPharma Corp.

CureDM, Inc.

CymaBay Therapeutics, Inc.

Daewoong Pharmaceutical Co., Ltd.

Daiichi Sankyo Company, Limited

Debiopharm International S.A.

Diabetica Limited

Diabetology Limited

DiaMedica Inc.

Diasome Pharmaceuticals, Inc.

DiscoveryBiomed, Inc.

Dong-A Socio Group

Eisai Co., Ltd.

Elcelyx Therapeutics, Inc.

Eli Lilly and Company

Enzo Biochem, Inc.

Esperion Therapeutics, Inc.

Evotec AG

Exsulin Corporation

Extrawell Pharmaceutical Holdings Limited

F. Hoffmann-La Roche Ltd.

Flamel Technologies S.A.

Foresee Pharmaceuticals, LLC

Generex Biotechnology Corporation

Genfit SA

Genovate Biotechnology Co., LTD.

Gilead Sciences, Inc.

GlaxoSmithKline plc

Glucox Biotech AB

GW Pharmaceuticals plc

Hadasit Medical Research Services & Development Ltd

Halozyme Therapeutics, Inc.

HanAll Biopharma Co., Ltd.

Handok Inc.

Hanmi Pharmaceuticals, Co. Ltd.

Harbor Therapeutics, Inc.

Heptares Therapeutics Ltd.

Hua Medicine Ltd.

Hybrigenics S.A.

Hyundai Pharmaceutical Co., Ltd.

Insusense Therapeutics ApS

Intarcia Therapeutics, Inc.

Integral Molecular, Inc.

Intercept Pharmaceuticals, Inc.

IPCA Laboratories Limited

Isis Pharmaceuticals, Inc.

Islet Sciences, Inc.

iTherX, Inc.

Japan Tobacco Inc.

Jenrin Discovery, Inc.

Jiangsu Hengrui Medicine Co., Ltd.

Johnson & Johnson

Kadmon Corporation, LLC

Kareus Therapeutics, SA

Kissei Pharmaceutical Co., Ltd.

Lexicon Pharmaceuticals, Inc.

LG Life Sciences, Ltd.

Ligand Pharmaceuticals, Inc.

Longevity Biotech, Inc

Medesis Pharma S.A.

Medestea Research & Production S.p.A.

MedImmune, LLC

Mellitech SAS

Merck & Co., Inc.

Mesoblast Limited

Metabolic Solutions Development Company, LLC

Metabolys S.A.S.

MI.TO. Technology S.r.L.

MidaSol Therapeutics LP

Mitsubishi Tanabe Pharma Corporation

Mochida Pharmaceutical Co., Ltd.

NeoPharm Co., Ltd.

Neurimmune Holding AG

Neurocrine Biosciences, Inc.

NGM Biopharmaceuticals, Inc.

Nordic Bioscience a/s

Novartis AG

Novo Nordisk A/S

Noxxon Pharma AG

Omeros Corporation

OPKO Health, Inc.

Oramed Pharmaceuticals, Inc.

Orbis Biosciences, Inc.

Orchid Chemicals & Pharmaceuticals Ltd

Orgenesis, Inc.

P2D Bioscience

Panacea Biotec Limited

Paras Biopharmaceuticals Finland Oy

Peptron, Inc.

Pfizer Inc.

PharmaIN Corporation

Pharnext SAS

PhaseBio Pharmaceuticals, Inc.

Piramal Enterprises Limited

PlasmaTech Biopharmaceuticals, Inc.

Poxel SA

Progen Pharmaceuticals Limited

Prometheon Pharma, LLC

ProMetic Life Sciences Inc.

ProteoTech, Inc.

Prothena Corporation plc

Ranbaxy Laboratories Limited

Reata Pharmaceuticals, Inc.

Receptos, Inc.

Red Glead Discovery AB

Regeneron Pharmaceuticals, Inc.

Regulus Therapeutics Inc.

Relypsa, Inc.

reMYND

Rhizen Pharmaceuticals SA

Rhythm Pharmaceuticals

Rigel Pharmaceuticals, Inc.

Sanofi

Sanwa Kagaku Kenkyusho Co., Ltd.

SBI Pharmaceuticals Co., Ltd.

Serodus ASA

Serometrix, LLC

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Shanghai Pharmaceutical Co., Ltd.

Shantani Proteome Analytics Pvt. Ltd.

Shionogi & Co., Ltd.

Shreya Life Sciences Pvt. Ltd.

SignPath Pharma Inc

Sihuan Pharmaceutical Holdings Group Ltd.

Sirona Biochem Corp

SK Chemicals Co., Ltd.

Starpharma Holdings Limited

Stelic Institute & Co.

Stempeutics Research Private Limited

Sumitomo Dainippon Pharma Co., Ltd.

Summit Corporation plc

Taisho Pharmaceutical Co., Ltd.

Takeda Pharmaceutical Company Limited

Teijin Pharma Limited

Teva Pharmaceutical Industries Limited

Theracos, Inc.

Thermalin Diabetes, LLC

Thetis Pharmaceuticals LLC

Toray Industries, Inc.

Torrent Pharmaceuticals Limited

Transgene Biotek Limited

Transition Therapeutics Inc.

TransTech Pharma, Inc.

TWi Pharmaceuticals, Inc.

Uni-Bio Science Group Ltd.

Upsher-Smith Laboratories, Inc.

Versartis, Inc.

Verva Pharmaceuticals Limited

Vicore Pharma AB

Virobay Inc.

Vitae Pharmaceuticals, Inc.

Vybion, Inc.

X-BODY BioSciences, Inc.

XBiotech USA, Inc.

Xenetic Biosciences plc

XL-protein GmbH

XOMA Corporation

Yuhan Corporation

Zafgen Inc.

Zealand Pharma A/S

Zydus Cadila Healthcare Limited

Type 2 Diabetes Therapeutic Products under Development, Key Players in Type 2 Diabetes Therapeutics, Type 2 Diabetes Pipeline Overview, Type 2 Diabetes Pipeline, Type 2 Diabetes Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com